Annual report pursuant to Section 13 and 15(d)

Segment, Geographical and Other Revenue Information - Segment Reporting (Details)

v3.20.4
Segment, Geographical and Other Revenue Information - Segment Reporting (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Segment Reporting Information [Line Items]      
Total revenues $ 69,056 $ 68,458 $ 60,594
Cost of product revenue 13,742 15,632 12,620
Research and development 44,185 33,873 29,978
Selling, general and administrative 35,049 31,502 29,291
Total costs and operating expenses 92,976 81,007 71,889
Income (loss) from operations (23,920) (12,549) (11,295)
Depreciation and amortization 1,950 1,570 1,147
United States (23,452) (11,751) (10,653)
Stock-based compensation 7,728 6,943 7,889
Performance Enzymes      
Segment Reporting Information [Line Items]      
Total revenues 48,106 58,156 47,073
Novel Biotherapeutics      
Segment Reporting Information [Line Items]      
Total revenues 20,950 10,302 13,521
Operating Segments      
Segment Reporting Information [Line Items]      
Total revenues 69,056 68,458 60,594
Cost of product revenue 13,742 15,632 12,620
Research and development 42,628 32,658 29,109
Selling, general and administrative 11,952 10,684 8,309
Total costs and operating expenses 68,322 58,974 50,038
Income (loss) from operations 734 9,484 10,556
Operating Segments | Performance Enzymes      
Segment Reporting Information [Line Items]      
Total revenues 48,106 58,156 47,073
Cost of product revenue 13,742 15,632 12,620
Research and development 20,923 19,380 18,924
Selling, general and administrative 9,597 8,462 7,538
Total costs and operating expenses 44,262 43,474 39,082
Income (loss) from operations 3,844 14,682 7,991
Stock-based compensation 2,970 2,303 2,591
Operating Segments | Novel Biotherapeutics      
Segment Reporting Information [Line Items]      
Total revenues 20,950 10,302 13,521
Cost of product revenue 0 0 0
Research and development 21,705 13,278 10,185
Selling, general and administrative 2,355 2,222 771
Total costs and operating expenses 24,060 15,500 10,956
Income (loss) from operations (3,110) (5,198) 2,565
Stock-based compensation 768 695 338
Corporate, Non-Segment      
Segment Reporting Information [Line Items]      
Total costs and operating expenses (22,306) (19,624) (20,324)
Depreciation and amortization 2,099 1,778 1,147
United States (23,671) (11,918) (10,915)
Stock-based compensation 3,990 3,945 4,960
Product revenue      
Segment Reporting Information [Line Items]      
Total revenues 30,220 29,465 25,590
Product revenue | Performance Enzymes      
Segment Reporting Information [Line Items]      
Total revenues 30,220 29,465 25,590
Product revenue | Novel Biotherapeutics      
Segment Reporting Information [Line Items]      
Total revenues 0 0 0
Product revenue | Operating Segments      
Segment Reporting Information [Line Items]      
Total revenues 30,220 29,465 25,590
Product revenue | Operating Segments | Performance Enzymes      
Segment Reporting Information [Line Items]      
Total revenues   29,465 25,590
Product revenue | Operating Segments | Novel Biotherapeutics      
Segment Reporting Information [Line Items]      
Total revenues   0 0
Research and development revenue      
Segment Reporting Information [Line Items]      
Total revenues 38,836 38,993 35,004
Research and development revenue | Performance Enzymes      
Segment Reporting Information [Line Items]      
Total revenues 17,886 28,691 21,483
Research and development revenue | Novel Biotherapeutics      
Segment Reporting Information [Line Items]      
Total revenues 20,950 10,302 13,521
Research and development revenue | Operating Segments      
Segment Reporting Information [Line Items]      
Total revenues $ 38,836 38,993 35,004
Research and development revenue | Operating Segments | Performance Enzymes      
Segment Reporting Information [Line Items]      
Total revenues   28,691 21,483
Research and development revenue | Operating Segments | Novel Biotherapeutics      
Segment Reporting Information [Line Items]      
Total revenues   $ 10,302 $ 13,521